Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
Maille E, Levallet J, Dubois F, Antoine M, Danel C, Creveuil C, Mazieres J, Margery J, Greillier L, Gounant V, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Bergot E, Langlais A, Morin F, Scherpereel A, Zalcman G, Levallet G. Maille E, et al. Among authors: zalcman g. Int J Cancer. 2022 Jun 1;150(11):1889-1904. doi: 10.1002/ijc.33997. Epub 2022 Mar 16. Int J Cancer. 2022. PMID: 35262190 Free PMC article. Clinical Trial.
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
Fouquet C, Antoine M, Tisserand P, Favis R, Wislez M, Commo F, Rabbe N, Carette MF, Milleron B, Barany F, Cadranel J, Zalcman G, Soussi T. Fouquet C, et al. Among authors: zalcman g. Clin Cancer Res. 2004 May 15;10(10):3479-89. doi: 10.1158/1078-0432.CCR-0994-03. Clin Cancer Res. 2004. PMID: 15161705
Sarcoidosis.
Bergot E, Paparel P, Zalcman G. Bergot E, et al. Among authors: zalcman g. N Engl J Med. 2008 Mar 27;358(13):1404; author reply 1404-5. N Engl J Med. 2008. PMID: 18376441 No abstract available.
Breast-cancer stromal cells with TP53 mutations.
Zalcman G, Bergot E, Hainaut P. Zalcman G, et al. N Engl J Med. 2008 Apr 10;358(15):1635-6; author reply 1636. N Engl J Med. 2008. PMID: 18411429 No abstract available.
Phosphodiesterase inhibitors for pulmonary hypertension.
Bergot E, Magnier R, Zalcman G. Bergot E, et al. Among authors: zalcman g. N Engl J Med. 2010 Feb 11;362(6):559; author reply 560. doi: 10.1056/NEJMc0912127. N Engl J Med. 2010. PMID: 20147727 No abstract available.
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D. Pluquet E, et al. Among authors: zalcman g. J Thorac Oncol. 2010 Apr;5(4):491-6. doi: 10.1097/JTO.0b013e3181cf0440. J Thorac Oncol. 2010. PMID: 20195171 Free article.
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D. Morère JF, et al. Among authors: zalcman g. Lung Cancer. 2010 Dec;70(3):301-7. doi: 10.1016/j.lungcan.2010.03.003. Epub 2010 Apr 18. Lung Cancer. 2010. PMID: 20400201 Clinical Trial.
312 results